Total Payments
$107,252
2024 Payments
$12,283
Companies
18
Transactions
107
Medicare Patients
811
Medicare Billing
$164,184
Payment Breakdown by Category
Other$52,031 (48.5%)
Consulting$48,621 (45.3%)
Research$2,329 (2.2%)
Food & Beverage$2,016 (1.9%)
Travel$1,962 (1.8%)
Education$292.95 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $51,431 | 23 | 48.0% |
| Consulting Fee | $48,621 | 25 | 45.3% |
| Unspecified | $2,329 | 5 | 2.2% |
| Food and Beverage | $2,016 | 39 | 1.9% |
| Travel and Lodging | $1,962 | 9 | 1.8% |
| Honoraria | $350.00 | 2 | 0.3% |
| Education | $292.95 | 3 | 0.3% |
| Grant | $250.00 | 1 | 0.2% |
Payments by Type
General
$104,923
102 transactions
Research
$2,329
5 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Daiichi Sankyo Inc. | $52,242 | 45 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $24,833 | 22 | $0 (2024) |
| Lilly USA, LLC | $12,495 | 4 | $0 (2023) |
| Eli Lilly and Company | $7,309 | 4 | $0 (2024) |
| PFIZER INC. | $5,717 | 9 | $0 (2023) |
| Stemline Therapeutics Inc. | $2,191 | 2 | $0 (2023) |
| Seagen Inc. | $1,686 | 5 | $0 (2022) |
| Athenex Pharmaceutical Division, LLC | $350.00 | 2 | $0 (2020) |
| Merck Sharp & Dohme LLC | $106.37 | 4 | $0 (2024) |
| PUMA BIOTECHNOLOGY, INC. | $85.30 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $12,283 | 19 | Daiichi Sankyo Inc. ($8,006) |
| 2023 | $31,024 | 26 | Daiichi Sankyo Inc. ($12,454) |
| 2022 | $32,572 | 26 | Daiichi Sankyo Inc. ($18,963) |
| 2021 | $16,880 | 18 | Lilly USA, LLC ($5,175) |
| 2020 | $11,771 | 12 | Daiichi Sankyo Inc. ($5,996) |
| 2019 | $2,597 | 4 | Daiichi Sankyo Inc. ($2,562) |
| 2018 | $104.52 | 1 | Lilly USA, LLC ($104.52) |
| 2017 | $21.06 | 1 | Genentech USA, Inc. ($21.06) |
All Payment Transactions
107 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/20/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $27.46 | General |
| Category: ONCOLOGY | ||||||
| 10/31/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,920.00 | General |
| Category: ONCOLOGY | ||||||
| 10/25/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $18.94 | General |
| Category: ONCOLOGY | ||||||
| 10/21/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $29.82 | General |
| Category: ONCOLOGY | ||||||
| 10/17/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,370.00 | General |
| 10/14/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $29.24 | General |
| Category: ONCOLOGY | ||||||
| 10/11/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Travel and Lodging | In-kind items and services | $61.64 | General |
| Category: ONCOLOGY | ||||||
| 10/09/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $114.48 | General |
| Category: ONCOLOGY | ||||||
| 09/11/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $72.25 | General |
| Category: Oncology | ||||||
| 09/11/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $18.65 | General |
| Category: Oncology | ||||||
| 09/06/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | In-kind items and services | $33.03 | General |
| Category: Oncology | ||||||
| 08/14/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $26.74 | General |
| Category: Rare Disease | ||||||
| 07/29/2024 | Eli Lilly and Company | VERZENIO (Drug) | Consulting Fee | Cash or cash equivalent | $2,400.00 | General |
| Category: Oncology | ||||||
| 07/02/2024 | AstraZeneca Pharmaceuticals LP | — | Grant | Cash or cash equivalent | $250.00 | General |
| 05/20/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,750.00 | General |
| Category: ONCOLOGY | ||||||
| 05/16/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Travel and Lodging | In-kind items and services | $17.42 | General |
| Category: ONCOLOGY | ||||||
| 05/16/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Travel and Lodging | In-kind items and services | $10.00 | General |
| Category: ONCOLOGY | ||||||
| 05/15/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $103.32 | General |
| Category: ONCOLOGY | ||||||
| 05/06/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $30.15 | General |
| Category: ONCOLOGY | ||||||
| 11/20/2023 | Daiichi Sankyo Inc. | Enhertu (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,100.00 | General |
| Category: ONCOLOGY | ||||||
| 11/20/2023 | Daiichi Sankyo Inc. | Enhertu (Drug) | Travel and Lodging | In-kind items and services | $78.73 | General |
| Category: ONCOLOGY | ||||||
| 11/16/2023 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $103.88 | General |
| Category: ONCOLOGY | ||||||
| 11/08/2023 | Daiichi Sankyo Inc. | Enhertu (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,100.00 | General |
| Category: ONCOLOGY | ||||||
| 11/08/2023 | Daiichi Sankyo Inc. | Enhertu (Drug) | Consulting Fee | Cash or cash equivalent | $1,027.50 | General |
| Category: ONCOLOGY | ||||||
| 11/07/2023 | Daiichi Sankyo Inc. | Enhertu (Drug) | Travel and Lodging | In-kind items and services | $37.73 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PALBOCICLIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $2,220 | 4 |
| EMBER-4: A RANDOMIZED OPEN-LABEL PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+ HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE | Eli Lilly and Company | $109.20 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 207 | 415 | $130,962 | $42,842 |
| 2022 | 4 | 259 | 531 | $165,130 | $56,830 |
| 2021 | 6 | 218 | 412 | $132,143 | $48,311 |
| 2020 | 3 | 127 | 225 | $61,449 | $16,201 |
Total Patients
811
Total Services
1,583
Medicare Billing
$164,184
Procedure Codes
16
All Medicare Procedures & Services
16 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 84 | 238 | $82,127 | $28,277 | 34.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 108 | 161 | $41,059 | $12,094 | 29.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 15 | 16 | $7,776 | $2,471 | 31.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 92 | 309 | $104,442 | $37,294 | 35.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 118 | 172 | $43,172 | $13,682 | 31.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 31 | 31 | $14,911 | $4,886 | 32.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 18 | 19 | $2,605 | $967.54 | 37.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 72 | 226 | $76,388 | $29,268 | 38.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 69 | 96 | $24,096 | $7,636 | 31.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 30 | 30 | $14,580 | $5,161 | 35.4% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 17 | 17 | $8,177 | $2,895 | 35.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 15 | 19 | $4,750 | $1,783 | 37.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 15 | 24 | $4,152 | $1,568 | 37.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 80 | 139 | $34,889 | $8,605 | 24.7% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 35 | 74 | $25,012 | $7,137 | 28.5% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 12 | 12 | $1,548 | $459.65 | 29.7% |
About Dr. Christopher Gallagher, M.D
Dr. Christopher Gallagher, M.D is a Hematology & Oncology healthcare provider based in Washington, District of Columbia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/09/2006. The National Provider Identifier (NPI) number assigned to this provider is 1467430579.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Christopher Gallagher, M.D has received a total of $107,252 in payments from pharmaceutical and medical device companies, with $12,283 received in 2024. These payments were reported across 107 transactions from 18 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($51,431).
As a Medicare-enrolled provider, Gallagher has provided services to 811 Medicare beneficiaries, totaling 1,583 services with total Medicare billing of $164,184. Data is available for 4 years (2020–2023), covering 16 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Washington, DC
- Active Since 01/09/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1467430579
Products in Payments
- Enhertu (Drug) $33,279
- ENHERTU (Drug) $18,963
- ENHERTU (Biological) $8,653
- IBRANCE (Drug) $3,519
- VERZENIO (Drug) $2,415
- Orserdu (Drug) $2,191
- TUKYSA (Drug) $1,393
- KEYTRUDA (Biological) $106.37
- NERLYNX (Drug) $85.30
- OPDUALAG (Drug) $36.87
- FOTIVDA (Drug) $33.03
- EPKINLY (Drug) $31.99
- Nplate (Biological) $29.26
- ULTOMIRIS (Biological) $26.74
- Tibsovo (Drug) $24.03
- TAGRISSO (Drug) $22.98
- Oncology (Device) $19.38
- Kadcyla (Biological) $15.33
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Washington
Imad Tabbara, M.d, M.D
Hematology & Oncology — Payments: $1.8M
Hematology & Oncology $1.8M
John Marshall
Hematology & Oncology — Payments: $770,250
Hematology & Oncology $770,250
Dr. Catherine Broome, Md, MD
Hematology & Oncology — Payments: $693,161
Hematology & Oncology $693,161
Craig Kessler
Hematology & Oncology — Payments: $632,186
Hematology & Oncology $632,186
Claudine Isaacs
Hematology & Oncology — Payments: $406,847
Hematology & Oncology $406,847
Muhammad Mirza, M.d, M.D
Hematology & Oncology — Payments: $118,419
Hematology & Oncology $118,419